Product
MabionCD20
1 clinical trial
1 indication
Indication
Rheumatoid ArthritisClinical trial
A Double-Blind, Randomized, Parallel-Group Study to Investigate the Pharmacokinetic and Clinical Similarity Between MabionCD20, EU-approved MabThera® and US-licensed Rituxan® in Patients With Moderate-to-Severe Rheumatoid ArthritisStatus: Withdrawn, Estimated PCD: 2023-08-03